… ProQR to Present at the Leerink Partners Global Healthcare … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR to Present at the LEERINK Partners Global Healthcare … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR to Present at the JMP Securities Life Science … be accessible from the 'Investor Relations' section of ProQR's website ( www.proqr.com ) under 'Events and Presentations'. The …
… ProQR to Present at Two Upcoming Investor Conferences in May … be accessible from the "Investor Relations" section of ProQR's website ( www.proqr.com ). The archived webcast will be available for …
… ProQR to Present at the 2015 Leerink Global Healthcare … be accessible from the "Investor Relations" section of ProQR's website ( www.proqr.com ). The archived webcast will be available for …
… ProQR to Present at Two Upcoming Investor Conferences in … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Announces Financial Results for the Second Quarter of … progress towards accomplishing the goals set out in ProQR’s Vision 2023 strategy, which includes starting the … property costs and other allocated costs. The increase in R&D expenses was primarily due to initiation of the clinical …
… ProQR Announces Virtual Presentations at American Academy of … Academy of Ophthalmology (AAO) held November 13-15, 2020. ProQR’s presentations Presentation title: Phase 1b/2 trial … Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced